Log In Sign up
The largest database of trusted experimental protocols
> Anatomy > Body Part > Liver

Liver

The liver is a vital organ responsible for numerous essential functions in the human body.
It plays a crucial role in metabolism, detoxification, and the production of essential proteins and enzymes.
The liver is involved in the regulation of blood sugar levels, the synthesis of cholesterol and other lipids, and the breakdown of drugs and other toxic substances.
Disorders affecting the liver can lead to a range of health issues, including cirrhosis, hepatitis, and liver cancer.
Ongoing research aims to elucidate the complex mechanisms underlying liver function and develop effective treatments for liver-related conditions.
Optimiing liver research protocols using advanced AI-driven tools like PubCompare.ai can help researchers identify the most effective approahces and maximize the impact of their work.

Most cited protocols related to «Liver»

1
Comparative Evaluation of RNA-seq and Microarray
Cited 2200 times
Genome-wide expression was measured in liver and kidney using RNA-seq on the Illumina GA I and hybridization of the same samples to Affymetrix HG-U133 Plus 2.0 arrays. The sample preparation and data analysis was designed to maximize the similarity between the microarray and RNA-seq experiments (see Marioni et al. [21 (link)]). Differential expression between kidney and liver was determined using an empirical Bayes modified t-statistic on the microarray platform and P-values for DE were downloaded from their website. For the RNA-seq experiment, the data were normalized using TMM normalization [27 ] and a negative binomial exact test was used to determine DE [16 (link)]. To test the GOseq method, we used the genes called DE from the microarray experiment to calculate the significance of over-representation of each GO category using the standard GO analysis methods. We also calculated P-values for each GO category being over-represented among genes that were DE in the RNA-seq data, using both the GOseq and hypergeometric methods. GOseq's ability to outperform the hypergeometric method, as measured by its ability to reproduce the results of the microarray GO analysis, was quantified by calculating a P-value for the difference in the two methods being due to chance. To do this, a NULL was chosen under which both methods were equally likely to correctly recover each microarray GO category, with this likelihood given by a binomial distribution.
Young M.D., Wakefield M.J., Smyth G.K, & Oshlack A. (2010). Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biology, 11(2), R14.
Full text: Click here
Publication 2010
Crossbreeding Genes Genome Kidney Liver Microarray Analysis RNA-Seq
2
Tissue-specific cDNA Library Generation
Cited 410 times
Double-stranded cDNA of eight human tissues (brain, heart, kidney, testis, liver, spleen, lung, and skeletal muscle) were generated with the Marathon cDNA amplification kit (Clontech). The cDNA concentration was normalized by quantitative PCR against AGPAT1 and EEF1A1 genes. The PCRs were performed in 386-well plates in a total volume of 12.5 μLl. One microliter of normalized cDNA was mixed with JumpStart REDTaq ReadyMix (Sigma) and primers (4 μM) with a Freedom evo robot (TECAN). The 10 first cycles of amplification were performed with a touchdown annealing temperature decreasing 1°C per cycle from 65°C to 55°C; annealing temperature of the next 30 cycles was carried out at 55°C. For each tissue, 2 μL of each RT-PCR reaction were pooled together and purified with the QIAquick PCR purification Kit (Qiagen) according to the manufacturer's recommendations. This purified DNA was directly used to generate a sequencing library with the “Genomic DNA sample prep kit” (Illumina) according to the manufacturer's recommendations with the exclusion of the fragmentation step. This library was subsequently sequenced on an Illumina Genome Analyzer 2 platform.
Harrow J., Frankish A., Gonzalez J.M., Tapanari E., Diekhans M., Kokocinski F., Aken B.L., Barrell D., Zadissa A., Searle S., Barnes I., Bignell A., Boychenko V., Hunt T., Kay M., Mukherjee G., Rajan J., Despacio-Reyes G., Saunders G., Steward C., Harte R., Lin M., Howald C., Tanzer A., Derrien T., Chrast J., Walters N., Balasubramanian S., Pei B., Tress M., Rodriguez J.M., Ezkurdia I., van Baren J., Brent M., Haussler D., Kellis M., Valencia A., Reymond A., Gerstein M., Guigó R, & Hubbard T.J. (2012). GENCODE: The reference human genome annotation for The ENCODE Project. Genome Research, 22(9), 1760-1774.
Publication 2012
Brain cDNA Library DNA, Complementary EEF1A1 protein, human Genes Genome Genomic Library Heart Homo sapiens Kidney Liver Lung Marathon composite resin Oligonucleotide Primers Reverse Transcriptase Polymerase Chain Reaction Skeletal Muscles Spleen Testis Tissues
3
Epidemiological Analysis of Early COVID-19 Cases
Cited 213 times
We obtained the medical records and compiled data for hospitalized patients and outpatients with laboratory-confirmed Covid-19, as reported to the National Health Commission between December 11, 2019, and January 29, 2020; the data cutoff for the study was January 31, 2020. Covid-19 was diagnosed on the basis of the WHO interim guidance.14 A confirmed case of Covid-19 was defined as a positive result on high-throughput sequencing or real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens.1 (link) Only laboratory-confirmed cases were included in the analysis.
We obtained data regarding cases outside Hubei province from the National Health Commission. Because of the high workload of clinicians, three outside experts from Guangzhou performed raw data extraction at Wuhan Jinyintan Hospital, where many of the patients with Covid-19 in Wuhan were being treated.
We extracted the recent exposure history, clinical symptoms or signs, and laboratory findings on admission from electronic medical records. Radiologic assessments included chest radiography or computed tomography (CT), and all laboratory testing was performed according to the clinical care needs of the patient. We determined the presence of a radiologic abnormality on the basis of the documentation or description in medical charts; if imaging scans were available, they were reviewed by attending physicians in respiratory medicine who extracted the data. Major disagreement between two reviewers was resolved by consultation with a third reviewer. Laboratory assessments consisted of a complete blood count, blood chemical analysis, coagulation testing, assessment of liver and renal function, and measures of electrolytes, C-reactive protein, procalcitonin, lactate dehydrogenase, and creatine kinase. We defined the degree of severity of Covid-19 (severe vs. nonsevere) at the time of admission using the American Thoracic Society guidelines for community-acquired pneumonia.15 (link)All medical records were copied and sent to the data-processing center in Guangzhou, under the coordination of the National Health Commission. A team of experienced respiratory clinicians reviewed and abstracted the data. Data were entered into a computerized database and cross-checked. If the core data were missing, requests for clarification were sent to the coordinators, who subsequently contacted the attending clinicians.
Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y, & Zhong N.S. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine.
Publication 2020
Biological Assay Blood Chemical Analysis Complete Blood Count COVID 19 C Reactive Protein Creatine Kinase Electrolytes Kidney Lactate Dehydrogenase Liver Nose Outpatients Patients Pharynx Physicians Pneumonia Procalcitonin Radiography, Thoracic Radionuclide Imaging Real-Time Polymerase Chain Reaction Respiratory Rate Reverse Transcriptase Polymerase Chain Reaction RNA-Directed DNA Polymerase X-Ray Computed Tomography
4
Comprehensive Evaluation of Fatty Liver Disease
Cited 194 times
Besides a clinical and laboratory evaluation, each subject underwent a liver ultrasonography, an anthropometric assessment and a 7-day diary of food intake (7DD) [1 (link)]. HBsAg and anti-HCV antibodies were assessed and subjects with anti-HCV antibodies underwent an HCV-RNA assessment to confirm HCV infection [1 (link),14 (link)]. ALT, aspartate transaminase (AST), GGT, glucose, triglycerides and cholesterol were measured by standard laboratory methods after 8-hr fasting. Insulin was measured by radio-immuno-assay (ADVIA Insulin Ready Pack 100, Bayer Diagnostics, Milan, Italy), with intra- and inter-assay coefficients of variation < 5%. FL was diagnosed by the same operator at ultrasonography [6 (link)]. Weight, stature, circumferences (waist and hip) and skinfolds (triceps, biceps, subscapular and suprailiac) were measured by two trained dietitians who had been standardized before and during the study according to standard procedures [15 ]. Body mass index (BMI) was calculated as weight (kg)/stature (m)2 and the sum of 4 skinfolds by summing triceps, biceps, subscapular and suprailiac skinfolds [16 (link),17 (link)]. The 7DD was administered to the subjects by two trained dietitians, who discussed it with the subject when she/he returned it one week later [18 (link)]. To avoid the confounding effect of seasonality on food intake, the 7DD diary was administered to a similar number of patients with and without SLD each month [19 ]. Mean daily ethanol intake was calculated as the mean value of ethanol intake as assessed by the 7DD [20 ]. The study protocol was approved and supervised by the Scientific Committee of the Fondo per lo Studio delle Malattie del Fegato (Trieste, Italy), and all subjects gave their written informed consent to participate.
Bedogni G., Bellentani S., Miglioli L., Masutti F., Passalacqua M., Castiglione A, & Tiribelli C. (2006). The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 6, 33.
Full text: Click here
Publication 2006
Aspartate Transaminase Biological Assay Body Height Cholesterol Dietitian Eating Ethanol Glucose Hepatitis B Surface Antigens Hepatitis C Hepatitis C Antibodies Index, Body Mass Insulin Liver Patients Radioimmunoassay Triglycerides Ultrasonography
5
Diagnostic Protocol for Novel Coronavirus
Cited 163 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Adenovirus Infections Adrenal Cortex Hormones Antibiotics Bacteria Biological Assay Blood Bronchi Bronchoalveolar Lavage Fluid Complete Blood Count COVID 19 Creatine Kinase Electrolytes Feces Genes, env Influenza Influenza in Birds isolation Kidney Lactate Dehydrogenase Liver Mechanical Ventilation Methylprednisolone Middle East Respiratory Syndrome Coronavirus Nasal Cannula Nose Oligonucleotide Primers Oseltamivir Oxygen Parainfluenza Pathogenicity Patients Pharynx Physical Examination Physicians Pneumonia Real-Time Polymerase Chain Reaction Respiratory Rate Respiratory Syncytial Virus Respiratory System SARS-CoV-2 Serum Severe acute respiratory syndrome-related coronavirus Sputum Tests, Blood Coagulation Tests, Diagnostic Therapeutics Treatment Protocols Virus Virus Release

Most recents protocols related to «Liver»

1
Biochemical Markers for Alcohol Use
Not available on PMC !

Example 22

Clinicians can use several biochemical measurements to objectively assess patients' current or past alcohol use. Several more experimental markers hold promise for measuring acute alcohol consumption and relapse. These include certain alcohol byproducts, such as acetaldehyde, ethyl glucuronide (EtG), and fatty acid ethyl esters (FAEE), as well as two measures of sialic acid, a carbohydrate that appears to be altered in alcoholics (Peterson K, Alcohol Research and Health, 2005). Clinicians have had access to a group of biomarkers that indicate a person's alcohol intake. Several of these reflect the activity of certain liver enzymes: serum gamma-glutamyltransferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and carbohydrate-deficient transferrin (CDT), a protein that has received much attention in recent years. Another marker, N-acetyl-β-hexosaminidase (beta-Hex), indicates that liver cells, as well as other cells, have been breaking down carbohydrates, which are found in great numbers in alcohol (Javors and Johnson 2003).

In some embodiments the disclosed device focuses on detecting markers associated with alcohol abuse from menstrual blood or cervicovaginal fluid.

US11864740B2. Sample collection and preservation devices, systems and methods (2024-01-09). NextGen Jane, Inc. [US]. Inventors: Ridhi Tariyal [US], Stephen K. Gire [US].
Full text: Click here
Patent 2024
Abuse, Alcohol Acetaldehyde Alcoholics Aspartate Transaminase Attention beta-N-Acetylhexosaminidase Biological Markers BLOOD carbohydrate-deficient transferrin Carbohydrates Cells D-Alanine Transaminase enzyme activity Esters Ethanol ethyl glucuronide Fatty Acids gamma-Glutamyl Transpeptidase Hepatocyte Liver Medical Devices Menstruation N-Acetylneuraminic Acid Patients Relapse Serum Staphylococcal Protein A
2
Evaluating Tucaresol and Checkpoint Inhibitors in Xenograft Models
Not available on PMC !

Example 7

Five groups including tucaresol, tucaresol plus PD-1 or PD-L1 antibody, tucaresol plus CTLA-4 antibody, CTLA-4 antibody plus PD-1 or PD-L1 antibody, and tucaresol plus plinabulin are tested to determine their effect in an animal xenograft model.

The combined treatment with tucaresol and the checkpoint inhibitor(s) is tested in comparison with the treatment with tucaresol alone, the treatment with checkpoint inhibitor alone, or combination of checkpoint inhibitors. The tests are performed using seven to ten-week old athymic (nu/nu) mice that were injected subcutaneously with human tumor cell lines (of either solid or liquid tumor origin, for example of breast, lung, colon, brain, liver, leukemia, myeloma, lymphoma, sarcoma, pancreatic or renal origin). Six to ten testing groups are prepared, and each group includes 10 mice.

Each treatment starts at tumor size between 40-150 mm3 and continues until Day 24-56, when the animals are necropsied. To determine the efficacy of each treatment, the following data are collected: mortality; the body weight of the mice assessed twice weekly both prior to treatments; the rate of tumor growth as determined by the tumor size measurement (twice every week); the tumor growth index; overall survival rate; the tumor weight at necropsy; and the time required to increase tumor size 10 fold.

US11857522B2. Compositions containing tucaresol or its analogs (2024-01-02). BeyondSpring Pharmaceuticals, Inc. [US]. Inventors: Ramon Mohanlal [US], Lan Huang [US], George Kenneth Lloyd [US].
Full text: Click here
Patent 2024
Animal Model Animals Autopsy Body Weight Brain Breast CD274 protein, human Cell Cycle Checkpoints Cell Line, Tumor Colon Combined Modality Therapy CTLA4 protein, human Genes, Neoplasm GZMB protein, human Heterografts Homo sapiens Immunoglobulins inhibitors Kidney Leukemia Liver Lung Lymphoma Mice, Nude Multiple Myeloma Mus Neoplasms Pancreas plinabulin Sarcoma Thymic aplasia tucaresol
3
Lipid Staining in Liver Tissue
Not available on PMC !

Example 18

Frozen tissue sections of liver were cut at 10 μm and air dried to the slides. After fixation in 10% formalin for 5 min, the slides were briefly washed with running tap water for 10 min, followed by rinse with 60{circumflex over ( )} isopropanol. Subsequently, oil red O working solution (0.3% oil red O) was used for lipid staining for 15 min. Slides were again rinsed with 60% isopropanol and then nuclei were lightly stained with alum haematoxylin, followed by rinse with distilled water and mounted in glycerine jelly. After half an hour, pictures were taken under microscopy.

Exemplary data are shown in FIG. 19, in which reduced lipid droplet amounts were observed after daily administration of mTA4 or mTA37 for 5 weeks.

US11865160B2. Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof (2024-01-09). THE SCRIPPS RESEARCH INSTITUTE [US]. Inventors: Weijun Shen [US], Pengyu Yang [US], Huafei Zou [US], Peter G. Schultz [US].
Full text: Click here
Patent 2024
alum, potassium Cell Nucleus Formalin Frozen Sections Glycerin Isopropyl Alcohol Lipid Droplet Lipids Liver Microscopy solvent red 27 Tissues
4
GaINAc-Conjugated siRNA/ASO Liver Targeting
Not available on PMC !

Example 8

In this experiment, siRNAs or ASOs targeting a target mRNA will be conjugated to a GaINAc moiety and administered to mice (n=5/group), and compared to a control experiment where the mice are administered siRNAs or ASOs without GaINAc conjugation. Mice are sacrificed 2 days later, and livers are frozen, later homogenized, and tested for target mRNA and protein expression. The amount of target mRNA or protein expression in the livers of mice treated with the GaINAc-conjugated siRNAs or ASOs is normalized and compared to the amount of GFP mRNA or protein expression in the livers of mice treated with the siRNAs or ASOs that are not GaINAc-conjugated. This may allow for a determination of the liver targeting ability of the GaINAc moiety. Multiple GaINAc moieties may be conjugated to the siRNAs or ASOs and compared to see which GaINAc moiety results in optimal liver targeting. The GaINAc moieties included in this experiment may be those that exhibit the greatest degree of hepatocyte targeting. The GaINAc moieties to be tested in these experiments may a GaINAc moiety described herein.

US11879125B2. GalNAc compositions for improving siRNA bioavailability (2024-01-23). EMPIRICO INC. [US]. Inventors: Darren H. Wakefield [US], David Rozema [US], Omri Gottesman [US].
Full text: Click here
Patent 2024
Freezing Hepatocyte Liver Mus Proteins RNA, Messenger RNA, Small Interfering
5
Cholesterol Metabolism in STAT1 Mice
Not available on PMC !

Example 9

CH25H was originally known to regulate cholesterol metabolism. However, when we compared the body weight, lipid deposition in liver and key enzymes involved in lipid metabolism, there was no significant change between WT and STAT1−/− mice (FIGS. 19A-19F). As shown in FIG. 19A, there was no significant difference of the body weight between APP/PS1 and APP/PS1/STAT1−/− mice. As shown in FIG. 19B, there was no significant difference in lipid deposition in liver cells between APP/PS1 and APP/PS1/STAT1−/− mice. Further, as shown in FIGS. 19C-19F, there were no significant difference of the expression of key enzymes including LPL, ABCA1, APOE, HMGCR between APP/PS1 and APP/PS1/STAT1−/− mice.

US11873321B2. Compositions and methods for treating alzheimer's disease (2024-01-16). Generos Biopharma Ltd. [CN]. Inventors: Xin-Yuan Fu [US], Yi Zhou [SG].
Full text: Click here
Patent 2024
ABCA1 protein, human ApoE protein, human Body Weight Cholesterol Enzymes Figs Hepatocyte HMGCR protein, human Lipid Metabolism Lipids Liver Metabolism Mice, Laboratory STAT1 protein, human

Top products related to «Liver»

1
Trizol reagent by Thermo Fisher Scientific
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
2
Rneasy mini kit by Qiagen
Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
3
Trizol by Thermo Fisher Scientific
Sourced in United States, Germany, China, Japan, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Belgium, Denmark, Netherlands, India, Ireland, Lithuania, Singapore, Sweden, Norway, Austria, Brazil, Argentina, Hungary, Sao Tome and Principe, New Zealand, Hong Kong, Cameroon, Philippines
TRIzol is a monophasic solution of phenol and guanidine isothiocyanate that is used for the isolation of total RNA from various biological samples. It is a reagent designed to facilitate the disruption of cells and the subsequent isolation of RNA.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
High capacity cdna reverse transcription kit by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, Japan, Lithuania, France, Italy, China, Spain, Canada, Switzerland, Poland, Australia, Belgium, Denmark, Sweden, Hungary, Austria, Ireland, Netherlands, Brazil, Macao, Israel, Singapore, Egypt, Morocco, Palestine, State of, Slovakia
The High-Capacity cDNA Reverse Transcription Kit is a laboratory tool used to convert RNA into complementary DNA (cDNA) molecules. It provides a reliable and efficient method for performing reverse transcription, a fundamental step in various molecular biology applications.
6
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
7
Fibroscan by Echosens
Sourced in France, United States
FibroScan is a non-invasive diagnostic device that uses vibration-controlled transient elastography (VCTE) technology to measure liver stiffness. The device transmits a mild vibration through the skin and measures the velocity of the resulting shear wave, which is directly related to the stiffness of the liver tissue. This information can be used to assess the degree of liver fibrosis.
8
Agilent 2100 bioanalyzer by Agilent Technologies
Sourced in United States, Germany, Canada, China, France, United Kingdom, Japan, Netherlands, Italy, Spain, Australia, Belgium, Denmark, Switzerland, Singapore, Sweden, Ireland, Lithuania, Austria, Poland, Morocco, Hong Kong, India
The Agilent 2100 Bioanalyzer is a lab instrument that provides automated analysis of DNA, RNA, and protein samples. It uses microfluidic technology to separate and detect these biomolecules with high sensitivity and resolution.
9
Oil red o by Merck Group
Sourced in United States, Germany, China, Japan, United Kingdom, Sao Tome and Principe, Italy, Macao, Australia, France, Switzerland, Spain, India, Poland, Canada
Oil Red O is a fat-soluble dye used in histology and cell biology for the staining of neutral lipids, such as triglycerides and cholesterol esters. It is a useful tool for the identification and visualization of lipid-rich structures in cells and tissues.
10
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.

More about "Liver"

The liver is a critical organ that plays a vital role in maintaining overall health and well-being.
As the body's primary detoxification center, the liver is responsible for metabolizing and breaking down a wide range of substances, including drugs, alcohol, and other toxins.
It also plays a crucial role in regulating blood sugar levels, synthesizing cholesterol and other lipids, and producing essential proteins and enzymes.
Liver disorders, such as cirrhosis, hepatitis, and liver cancer, can have serious health consequences and often require specialized treatment.
Ongoing research in the field of hepatology, the study of the liver, aims to better understand the complex mechanisms underlying liver function and develop more effective therapies for liver-related conditions.
Optimizing liver research protocols using advanced AI-driven tools like PubCompare.ai can help researchers identify the most effective approaches and maximize the impact of their work.
PubCompare.ai allows researchers to effortlessly locate the best protocols from literature, pre-prints, and patents using its AI-powered comparisons, enabling them to identify the most effective products and optimize their research processes for maximum impact.
In addition to PubCompare.ai, researchers may also utilize other tools and techniques to study the liver, such as TRIzol reagent and the RNeasy Mini Kit for RNA extraction, the High-Capacity cDNA Reverse Transcription Kit for gene expression analysis, and DMEM and FBS for cell culture experiments.
Techniques like FibroScan, Agilent 2100 Bioanalyzer, and Oil Red O staining can also be employed to assess liver function and structure.
By leveraging these advanced tools and techniques, researchers can gain deeper insights into the complexities of liver biology and develop more effective treatments for liver-related disorders, ultimately improving patient outcomes and enhancing overall public health.